PTC Therapeutics (PTCT) awards stock units and options to director

Rhea-AI Filing Summary

PTC Therapeutics director Jerome B. Zeldis reported new equity awards from the company. On January 2, 2026, he received 4,000 shares of common stock in the form of restricted stock units, bringing his directly held common shares to 22,500. These RSUs vest over one year, with five-twelfths vesting on June 2, 2026 and the remaining seven-twelfths on January 2, 2027. He has elected to defer receipt of all vested shares until the earliest of four years from grant, six months after separation of service, a change in control event, or death.

On the same date, he was also granted a stock option for 3,475 shares of common stock with an exercise price of $76.74 per share. This option vests in twelve equal monthly installments over one year starting February 2, 2026 and expires on January 1, 2036.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider ZELDIS JEROME B

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	3,475	$0.00	--
Grant/Award	Common Stock	4,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 3,475 shares (Direct); Common Stock — 22,500 shares (Direct)

Footnotes (1)

1. Restricted stock units granted on January 2, 2026 that vest over one year, with five-twelfths (5/12) of the shares underlying the RSUs vesting on June 2, 2026 and the remaining seven-twelfths (7/12) of the original shares underlying the RSUs vesting on January 2, 2027. The Reporting Person has elected to defer receipt of all vested shares until the earliest to occur of (i) four years from the date of grant and (ii) the earliest to occur of (a) the date that is six months following separation of service from the Issuer, (b) a change in control event and (c) death. This option was granted on January 2, 2026 and vests over one year in twelve equal monthly installments, commencing on February 2, 2026.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ZELDIS JEROME B

(Last) (First) (Middle)

C/O PTC THERAPEUTICS, INC.

500 WARREN CORPORATE CENTER DRIVE

(Street)

WARREN NJ 07059

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PTC THERAPEUTICS, INC. [ PTCT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/02/2026		A		4,000(1)	A	$0	22,500	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$76.74	01/02/2026		A		3,475		(2)	01/01/2036	Common Stock	3,475	$0	3,475	D

Explanation of Responses:

1. Restricted stock units granted on January 2, 2026 that vest over one year, with five-twelfths (5/12) of the shares underlying the RSUs vesting on June 2, 2026 and the remaining seven-twelfths (7/12) of the original shares underlying the RSUs vesting on January 2, 2027. The Reporting Person has elected to defer receipt of all vested shares until the earliest to occur of (i) four years from the date of grant and (ii) the earliest to occur of (a) the date that is six months following separation of service from the Issuer, (b) a change in control event and (c) death.

2. This option was granted on January 2, 2026 and vests over one year in twelve equal monthly installments, commencing on February 2, 2026.

	/s/ Avraham S. Adler, Attorney-in-Fact	01/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What equity awards did PTC Therapeutics (PTCT) director Jerome B. Zeldis receive?

Jerome B. Zeldis received 4,000 restricted stock units of PTC Therapeutics common stock and a stock option for 3,475 shares with an exercise price of $76.74 per share, both granted on January 2, 2026.

How do the new RSUs granted to Jerome B. Zeldis at PTC Therapeutics vest?

The 4,000 RSUs granted on January 2, 2026 vest over one year: five-twelfths of the shares vest on June 2, 2026 and the remaining seven-twelfths vest on January 2, 2027.

When will Jerome B. Zeldis actually receive the vested RSU shares from PTC Therapeutics?

Jerome B. Zeldis elected to defer receipt of all vested RSU shares until the earliest of four years from the grant date, six months after separation of service, a change in control event, or death.

What are the key terms of Jerome B. Zeldis’s stock option from PTC Therapeutics?

The stock option covers 3,475 shares of common stock at an exercise price of $76.74 per share. It was granted on January 2, 2026, vests in twelve equal monthly installments starting February 2, 2026, and expires on January 1, 2036.

How many PTC Therapeutics common shares does Jerome B. Zeldis hold after these grants?

Following the reported RSU-related acquisition, Jerome B. Zeldis beneficially owns 22,500 shares of PTC Therapeutics common stock directly.

Is Jerome B. Zeldis a 10% owner of PTC Therapeutics based on this filing?

The filing identifies Jerome B. Zeldis as a director of PTC Therapeutics and does not mark him as a 10% owner.